Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 158

1.

Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery.

Rabban JT, Garg K, Crawford B, Chen LM, Zaloudek CJ.

Am J Surg Pathol. 2014 Jun;38(6):729-42. doi: 10.1097/PAS.0000000000000199.

PMID:
24820399
[PubMed - indexed for MEDLINE]
2.

Serous tubal intraepithelial carcinoma in a Japanese woman with a deleterious BRCA1 mutation.

Ishikawa H, Kiyokawa T, Utsuno E, Matsushita K, Nomura F, Shozu M.

Jpn J Clin Oncol. 2014 Jun;44(6):597-601. doi: 10.1093/jjco/hyu035. Epub 2014 Apr 9.

PMID:
24719479
[PubMed - indexed for MEDLINE]
3.

Better therapeutic trials in ovarian cancer.

Bookman MA, Gilks CB, Kohn EC, Kaplan KO, Huntsman D, Aghajanian C, Birrer MJ, Ledermann JA, Oza AM, Swenerton KD.

J Natl Cancer Inst. 2014 Apr;106(4):dju029. doi: 10.1093/jnci/dju029. Epub 2014 Mar 13. Review.

PMID:
24627272
[PubMed - indexed for MEDLINE]
4.

Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.

Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE, Kaklamani VG; Northwestern Cancer Genetics Group.

Cancer. 2014 May 15;120(10):1557-64. doi: 10.1002/cncr.28577. Epub 2014 Feb 12.

PMID:
24522996
[PubMed - indexed for MEDLINE]
5.

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A.

Cancer Res. 2014 Jan 1;74(1):287-97. doi: 10.1158/0008-5472.CAN-13-2541. Epub 2013 Nov 15.

PMID:
24240700
[PubMed - indexed for MEDLINE]
6.

Hereditary ovarian and breast cancer: what have we learned?

Lynch HT, Snyder C, Casey MJ.

Ann Oncol. 2013 Nov;24 Suppl 8:viii83-viii95. doi: 10.1093/annonc/mdt313. Review.

PMID:
24131978
[PubMed - indexed for MEDLINE]
7.

Alternatives to risk-reducing surgery for ovarian cancer.

Gadducci A, Sergiampietri C, Tana R.

Ann Oncol. 2013 Nov;24 Suppl 8:viii47-viii53. doi: 10.1093/annonc/mdt311. Review.

PMID:
24131970
[PubMed - indexed for MEDLINE]
8.

Coming into focus: the nonovarian origins of ovarian cancer.

Dubeau L, Drapkin R.

Ann Oncol. 2013 Nov;24 Suppl 8:viii28-viii35. doi: 10.1093/annonc/mdt308. Review.

PMID:
24131966
[PubMed - indexed for MEDLINE]
9.

Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype.

Chui MH, Gilks CB, Cooper K, Clarke BA.

Adv Anat Pathol. 2013 Nov;20(6):378-86. doi: 10.1097/PAP.0b013e3182a92cf8. Review.

PMID:
24113308
[PubMed - indexed for MEDLINE]
10.

The different impact of BRCA mutations on the survival of epithelial ovarian cancer patients: a retrospective single-center experience.

Lorusso D, Cirillo F, Mancini M, Spatti GB, Grijuela B, Ditto A, Raspagliesi F.

Oncology. 2013;85(2):122-7. doi: 10.1159/000353786. Epub 2013 Aug 13.

PMID:
23941904
[PubMed - indexed for MEDLINE]
11.

Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.

Ross JS, Ali SM, Wang K, Palmer G, Yelensky R, Lipson D, Miller VA, Zajchowski D, Shawver LK, Stephens PJ.

Gynecol Oncol. 2013 Sep;130(3):554-9. doi: 10.1016/j.ygyno.2013.06.019. Epub 2013 Jun 20.

PMID:
23791828
[PubMed - indexed for MEDLINE]
Free Article
12.

Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma.

Novetsky AP, Smith K, Babb SA, Jeffe DB, Hagemann AR, Thaker PH, Powell MA, Mutch DG, Massad LS, Zighelboim I.

Int J Gynecol Cancer. 2013 Jul;23(6):1016-21. doi: 10.1097/IGC.0b013e3182994365.

PMID:
23748176
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors.

Pedroni M, Di Gregorio C, Cortesi L, Reggiani Bonetti L, Magnani G, Simone ML, Medici V, Priore Oliva C, Marino M, Ponz de Leon M.

Tech Coloproctol. 2014 Mar;18(3):285-9. doi: 10.1007/s10151-013-1030-y. Epub 2013 May 22.

PMID:
23695190
[PubMed - in process]
14.

Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.

Secord AA, Barnett JC, Ledermann JA, Peterson BL, Myers ER, Havrilesky LJ.

Int J Gynecol Cancer. 2013 Jun;23(5):846-52. doi: 10.1097/IGC.0b013e31829527bd.

PMID:
23666017
[PubMed - indexed for MEDLINE]
15.

Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions.

Chene G, Tchirkov A, Pierre-Eymard E, Dauplat J, Raoelfils I, Cayre A, Watkin E, Vago P, Penault-Llorca F.

Clin Cancer Res. 2013 Jun 1;19(11):2873-82. doi: 10.1158/1078-0432.CCR-12-3947. Epub 2013 Apr 15.

PMID:
23589176
[PubMed - indexed for MEDLINE]
Free Article
16.

Mutation analysis of the SHFM1 gene in breast/ovarian cancer families.

Bonache S, de la Hoya M, Gutierrez-Enriquez S, Tenés A, Masas M, Balmaña J, Diez O.

J Cancer Res Clin Oncol. 2013 Mar;139(3):529-32. doi: 10.1007/s00432-013-1385-5. Epub 2013 Feb 1.

PMID:
23371468
[PubMed - indexed for MEDLINE]
17.

BRCA1 and BRCA2 mutations in the ovarian cancer population across race and ethnicity: special reference to Asia.

Shanmughapriya S, Nachiappan V, Natarajaseenivasan K.

Oncology. 2013;84(4):226-32. doi: 10.1159/000346593. Epub 2013 Jan 29. Review.

PMID:
23364291
[PubMed - indexed for MEDLINE]
18.

Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.

Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, Levanon K, Sougnez C, Tsherniak A, Gomez S, Onofrio R, Gabriel S, Chin L, Zhang N, Spellman PT, Zhang Y, Akbani R, Hoadley KA, Kahn A, Köbel M, Huntsman D, Soslow RA, Defazio A, Birrer MJ, Gray JW, Weinstein JN, Bowtell DD, Drapkin R, Mesirov JP, Getz G, Levine DA, Meyerson M; Cancer Genome Atlas Research Network.

J Clin Invest. 2013 Jan 2;123(1):517-25. doi: 10.1172/JCI65833. Epub 2012 Dec 21.

PMID:
23257362
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.

Pennington KP, Wickramanayake A, Norquist BM, Pennil CC, Garcia RL, Agnew KJ, Taniguchi T, Welcsh P, Swisher EM.

Gynecol Oncol. 2013 Mar;128(3):493-9. doi: 10.1016/j.ygyno.2012.12.007. Epub 2012 Dec 12.

PMID:
23246380
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Ovarian cancer : making its own rules-again.

Kohn EC, Hurteau J.

Cancer. 2013 Feb 1;119(3):474-6. doi: 10.1002/cncr.27833. Epub 2012 Dec 11. Review. No abstract available.

PMID:
23233093
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk